165 related articles for article (PubMed ID: 30448319)
1. Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay.
Moreira WC; Machado NS; Freitas JFS; Almeida AECC; Moura WC
J Virol Methods; 2019 Feb; 264():31-37. PubMed ID: 30448319
[TBL] [Abstract][Full Text] [Related]
2. Development and pre-validation of a quantitative multi-dose serological assay for potency testing of inactivated rabies vaccines for human use.
Moreira WC; Freitas JFS; Machado NS; Almeida AECC; Moura WC
J Virol Methods; 2019 Jan; 263():54-59. PubMed ID: 30393149
[TBL] [Abstract][Full Text] [Related]
3. An electrochemiluminescence assay for analysis of rabies virus glycoprotein content in rabies vaccines.
Smith TG; Ellison JA; Ma X; Kuzmina N; Carson WC; Rupprecht CE
Vaccine; 2013 Jul; 31(33):3333-8. PubMed ID: 23742991
[TBL] [Abstract][Full Text] [Related]
4. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.
Koraka P; Bosch BJ; Cox M; Chubet R; Amerongen Gv; Lövgren-Bengtsson K; Martina BE; Roose J; Rottier PJ; Osterhaus AD
Vaccine; 2014 Aug; 32(36):4644-50. PubMed ID: 24962755
[TBL] [Abstract][Full Text] [Related]
5. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein.
Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM
J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752
[TBL] [Abstract][Full Text] [Related]
6. G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P
Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of multi-epitope-based vaccine candidates administered with the adjuvant Gp96 against rabies.
Niu Y; Liu Y; Yang L; Qu H; Zhao J; Hu R; Li J; Liu W
Virol Sin; 2016 Apr; 31(2):168-75. PubMed ID: 27068655
[TBL] [Abstract][Full Text] [Related]
8. A multi-dose serological assay suitable to quantify the potency of inactivated rabies vaccines for veterinary use.
Krämer B; Kamphuis E; Hanschmann KM; Milne C; Daas A; Duchow K
Biologicals; 2013 Nov; 41(6):400-6. PubMed ID: 24144483
[TBL] [Abstract][Full Text] [Related]
9. Target cells for antibodies detection in rabies vaccine control.
Fontana D; Prieto C; Kratje R; Etcheverrigaray M
Vaccine; 2014 May; 32(24):2805-7. PubMed ID: 24631076
[TBL] [Abstract][Full Text] [Related]
10. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.
Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y
Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the immunogenicity of two inactivated recombinant rabies viruses overexpressing the glycoprotein.
Navid MT; Li Y; Zhou M; Cui M; Fu ZF; Tang L; Zhao L
Arch Virol; 2016 Oct; 161(10):2863-70. PubMed ID: 27438075
[TBL] [Abstract][Full Text] [Related]
12. A thermostable messenger RNA based vaccine against rabies.
Stitz L; Vogel A; Schnee M; Voss D; Rauch S; Mutzke T; Ketterer T; Kramps T; Petsch B
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006108. PubMed ID: 29216187
[TBL] [Abstract][Full Text] [Related]
13. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency.
Turki I; Hammami A; Kharmachi H; Mousli M
Mol Immunol; 2014 Feb; 57(2):66-73. PubMed ID: 24091293
[TBL] [Abstract][Full Text] [Related]
14. Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle.
Piza AT; Pieri KM; Lusa GM; Caporale GM; Terreran MT; Machado LA; Zanetti CR
Mem Inst Oswaldo Cruz; 2002 Mar; 97(2):265-8. PubMed ID: 12016455
[TBL] [Abstract][Full Text] [Related]
15. A DNA vaccine that encodes rabies virus glycoprotein lacking transmembrane domain enhances antibody response but not protection.
Gupta PK; Sharma S; Walunj SS; Patil AA; Rai A; Saini M
Acta Virol; 2006; 50(2):87-92. PubMed ID: 16808325
[TBL] [Abstract][Full Text] [Related]
16. Fusion Peptide Improves Stability and Bioactivity of Single Chain Antibody against Rabies Virus.
Xi H; Zhang K; Yin Y; Gu T; Sun Q; Shi L; Zhang R; Jiang C; Kong W; Wu Y
J Microbiol Biotechnol; 2017 Apr; 27(4):718-724. PubMed ID: 28068664
[TBL] [Abstract][Full Text] [Related]
17. Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus.
Luo J; Shi H; Tan Y; Niu X; Long T; Zhao J; Tian Q; Wang Y; Chen H; Guo X
Vaccine; 2016 Aug; 34(37):4392-8. PubMed ID: 27449079
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies.
Welch RJ; Anderson BL; Litwin CM
J Med Microbiol; 2009 Jun; 58(Pt 6):806-810. PubMed ID: 19429758
[TBL] [Abstract][Full Text] [Related]
19. A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies.
Borhani K; Ajorloo M; Bamdad T; Mozhgani SH; Ghaderi M; Gholami AR
Arch Iran Med; 2015 Apr; 18(4):223-7. PubMed ID: 25841942
[TBL] [Abstract][Full Text] [Related]
20. Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.
Kang H; Qi Y; Wang H; Zheng X; Gao Y; Li N; Yang S; Xia X
Viruses; 2015 Mar; 7(3):1134-52. PubMed ID: 25768031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
